R U OK?
The Novel Therapeutic Potential of R Channels in Epilepsy

Ca,2.3 Channels Are Critical for Oscillatory Burst Discharges in the Reticular Thalamus and Absence Epilepsy.

Neurons of the reticular thalamus (RT) display oscillatory burst discharges that are believed to be critical for thalamocortical network oscillations related to absence epilepsy. Ca2+-dependent mechanisms underlie such oscillatory discharges. However, involvement of high-voltage activated (HVA) Ca2+ channels in this process has been discounted. We examined this issue closely using mice deficient for the HVA Ca,2.3 channels. In brain slices of Ca,2.3−/−, a hyperpolarizing current injection initiated a low-threshold burst of spikes in RT neurons; however, subsequent oscillatory burst discharges were severely suppressed, with a significantly reduced slow afterhyperpolarization (AHP). Consequently, the lack of Ca,2.3 resulted in a marked decrease in the sensitivity of the animal to γ-butyrolactone-induced absence epilepsy. Local blockade of Ca,2.3 channels in the RT mimicked the results of Ca,2.3−/− mice. These results provide strong evidence that Ca,2.3 channels are critical for oscillatory burst discharges in RT neurons and for the expression of absence epilepsy.

Commentary
Absence epilepsy—the most common form of childhood epileptic disorders—is characterized by a brief and frequent loss of consciousness associated with generalized spike-and-wave discharges (1). These discharges represent synchronized oscillations in the corticothalamic system in which the thalamus is proposed to be an essential rhythm generator (2), although the role of the thalamus versus the cortex in absence seizure initiation remains controversial (3–5). The corticothalamic system is composed of reciprocally connected excitatory thalamocortical and corticothalamic pathways along with a key intervening structure, the reticular thalamus (RT). Both sets of long-range excitatory projections—the cortical and thalamocortical glutamatergic axons—emit axon collateral branches en route to their final targets to activate the GABAergic neurons within the RT. This leads to burst firing of RT cells and powerful inhibitory output to thalamocortical relay neurons, which paradoxically leads to reentrant circuit activation through postinhibitory burst firing. Oscillations are thought to arise and be sustained in the thalamocortical network through cyclical excitation, which is phased by the inhibitory output of RT. Thus a key element in generation of neural oscillations in thalamocortical circuits is the oscillatory burst activity in RT neurons, which is critical for the expression of spike-and-wave discharges (6). Therefore, the mechanisms underlying the bursting activity in this nucleus are of paramount importance. In particular, T-type calcium currents are thought to underlie the low-threshold calcium burst firing mode. Indeed, T currents and the bursts are reduced by ethosuximide (7, 8), which is a first choice anti-absence therapy (9).

In 1993, Soong et al. reported the cloning of a T-type voltage-gated calcium channel: “rbE-II channel” (10). This channel ultimately turned out to be the R-type channel (Ca,2.3) (11), and distinct from the “classic” T-type channel mediated by Ca,3 channel family (12). In a recent study, Zaman et al. provided the first compelling evidence that the R current does act as a T-type calcium current in that it strongly contributes to the calcium-dependent burst firing mode in the RT neurons and to absence epilepsy.

R channels are densely expressed in the cortex and RT but not in thalamocortical neurons. Although R channels are structurally related to high-voltage-activated calcium channels, some of their electrophysiological properties are closer to those of T channels (10), yet their activation threshold is ~25 mV more depolarized (11). Given the differences in their biophysical properties, T channels are more suitable for supporting slow pacemaker activity such as postinhibitory rebound, whereas R channels do provide more rapid, transient surges of calcium (11). While the role of T current in bursting of RT cells has been extensively studied, the involvement of R channels in this activity remained obscure.

Zaman et al. examined this issue using Ca,2.3−/− mice. The investigators demonstrate for the first time that R channels play a major role in both supporting the burst firing mode in RT neurons and in experimental absence epilepsy. Using the state-of-art electrophysiological patch clamp techniques from brain slice preparations, Zaman et al. show that in wild-type RT cells postinhibitory rebound activation of T channels leads to depolarization and recruitment of R channels with a resultant
enhanced burst response. In addition, R channel activation appears to be particularly effective in promoting calcium-dependent slow afterhyperpolarization (AHP) in RT cells, which enhances repetitive burst firing and is critical for intrinsic rhythmic discharge in the RT neurons that would reinforce synaptic network activity. In Ca_{v2.3}^{−/−} mice, the strength of the rebound burst as well as the postburst AHP were reduced, and the ability of the neuron to discharge oscillatory bursts was abolished. All these alterations in bursting properties of RT cells were faithfully mimicked in the wild-type mouse by SNX-482—a specific blocker of R channels. Thus, the authors convincingly showed that the reduced bursting properties in the Ca_{v2.3}^{−/−} mouse resulted directly from lack of R channels rather than from compensatory reduction in the T current and confirmed that T currents were not reduced.

Given that bursting firing properties in RT neurons are critical in the expression of absence seizures (6), and that R channels enhance the burst strength and the propensity of the cell to fire rhythmic bursts (see above), the authors asked whether blocking R channels in RT could be antiepileptic. In order to answer this question, EEG recordings were performed in wild-type and Ca_{v2.3}^{−/−} mice to compare the susceptibility of these mice to gamma-butyrolactone (GBL)-induced spike-and-wave discharges—a well-established pharmacologic model of absence epilepsy. Although systemic administration of GBL induced typical spike-and-wave discharges in all genotypes, their duration was significantly reduced in Ca_{v2.3}^{−/−} mice compared with wild-type Ca_{v2.3}^{+/+} mice and was intermediate in Ca_{v2.3}^{+/−} mice, suggesting a gene-dosage effect. Also, the lack of Ca_{v2.3} was associated with a tendency toward a delay in the onset of GBL-induced seizures.

Based on these results alone, it was not possible to exclude the possibility that the reduced severity of seizures in Ca_{v2.3}^{−/−} mice resulted at least in part from lack of R channels in the cerebral cortex—a major factor in the expression of absence seizures. To determine whether the reduced seizure susceptibility of Ca_{v2.3}^{−/−} mice resulted from lack of R channels in RT, the authors performed a technically challenging experiment consisting of local injections of the R-type selective channel blocker SNX-482 bilaterally into the RT of wild-type mice while examining susceptibility to GBL-induced seizures. Strikingly, SNX-482 injections in the RT of wild-type mice phenocopied the results from the Ca_{v2.3}^{−/−} mice (i.e., reduced the duration of GBL-induced spike-and-wave discharges and induced a tendency to a delayed onset). These results are interesting in the context of the recent controversy regarding the role of the cortex versus the thalamus in the expression of absence seizures, as they reinforce the concept that the thalamus plays an active rhythmogenic role. Several studies in genetic rat models of absence epilepsy have reported that the cortex has a leading role in seizure initiation (13, 14). While abnormalities in either the cortex or thalamus could initiate absence seizures (5), the present study demonstrates that specifically targeting the RT excitability could be a therapeutic approach for treating the seizures.

Absence epilepsy can have multifactorial genetic origins (1). Whether or not mutations in genes encoding for R channels are associated with the human epilepsy is unknown. Given the seizure-suppressing effects of R channel blockade by Zaman et al., one could speculate that upregulation of this channel could be pro-epileptic and could be associated with human absence epilepsy.

Finally, this study leads to the idea that targeting R channels could be a novel therapeutic approach, potentially useful in cases where absence epilepsy is refractory to conventional antiepileptic medications. Indeed, combining R-channel blockers with T-channel blockers would have a synergistic effect on thalamic burst firing and might increase the efficacy over current antiepileptic monotherapies.

by Jeanne T. Paz and John R. Huguenard

References


American Epilepsy Society
Epilepsy Currents Journal
Disclosure of Potential Conflicts of Interest

Instructions
The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. **Identifying information.**
Enter your full name. If you are NOT the main contributing author, please check the box “no” and enter the name of the main contributing author in the space that appears. Provide the requested manuscript information.

2. **The work under consideration for publication.**
This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”. Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. **Relevant financial activities outside the submitted work.**
This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. **Other relationships**
Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.
Section #1 Identifying Information

1. Today’s Date: 02/14/2010
2. First Name  John     Last Name Huguenard  Degree PhD
3. Are you the Main Assigned Author?  ☒ Yes  ☐ No
   If no, enter your name as co-author:
4. Manuscript/Article Title: R U OK?  The novel therapeutic potential of R channels in epilepsy
5. Journal Issue you are submitting for:  12.1

Section #2 The Work Under Consideration for Publication
Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Complete each row by checking “No” or providing the requested information.  If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Grant</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consulting fee or honorarium</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Support for travel to meetings for the study or other purposes</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Fees for participating in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Payment for writing or reviewing the manuscript</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Provision of writing assistance, medicines, equipment, or administrative support.</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Other</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts on this study.
** Use this section to provide any needed explanation.
### Section #3 Relevant financial activities outside the submitted work.
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add” box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type of relationship (in alphabetical order)</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Board membership</td>
<td>❑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consultancy</td>
<td>❑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Employment</td>
<td>❑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Expert testimony</td>
<td>☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Grants/grants pending</td>
<td>☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Payment for lectures including service on speakers bureaus</td>
<td>❑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Payment for manuscript preparation.</td>
<td>❑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Patents (planned, pending or issued)</td>
<td>❑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Royalties</td>
<td>☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Payment for development of educational presentations</td>
<td>❑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Stock/stock options</td>
<td>❑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Travel/accommodations/meeting expenses unrelated to activities listed.**</td>
<td>❑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Other (err on the side of full disclosure)</td>
<td>❑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.
** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

### Section #4 Other relationships
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☑ No other relationships/conditions/circumstances that present a potential conflict of interest.
☐ Yes, the following relationships/conditions/circumstances are present:

Thank you for your assistance.

*Epilepsy Currents* Editorial Board